IRIS
RENI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.666
NA - Nord America 4.138
EU - Europa 2.728
SA - Sud America 2.459
AF - Africa 146
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 5
Totale 16.152
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.929
SG - Singapore 2.668
BR - Brasile 2.085
CN - Cina 1.783
HK - Hong Kong 998
SE - Svezia 837
VN - Vietnam 690
IT - Italia 551
RU - Federazione Russa 376
DE - Germania 277
AR - Argentina 165
GB - Regno Unito 145
FI - Finlandia 142
IN - India 113
CA - Canada 105
BD - Bangladesh 81
EC - Ecuador 71
NL - Olanda 71
MX - Messico 70
ID - Indonesia 68
PL - Polonia 68
ZA - Sudafrica 66
FR - Francia 56
JP - Giappone 43
AT - Austria 42
IE - Irlanda 41
IQ - Iraq 35
TR - Turchia 34
CO - Colombia 33
PY - Paraguay 33
ES - Italia 29
VE - Venezuela 24
UA - Ucraina 23
MA - Marocco 22
PK - Pakistan 21
CL - Cile 19
UZ - Uzbekistan 18
PE - Perù 17
EG - Egitto 14
LT - Lituania 13
AE - Emirati Arabi Uniti 12
TN - Tunisia 12
KE - Kenya 11
AL - Albania 10
IR - Iran 10
CZ - Repubblica Ceca 9
KZ - Kazakistan 9
SA - Arabia Saudita 9
AZ - Azerbaigian 8
BE - Belgio 8
EU - Europa 7
LB - Libano 7
NP - Nepal 7
OM - Oman 7
IL - Israele 6
UY - Uruguay 6
BH - Bahrain 5
BY - Bielorussia 5
CR - Costa Rica 5
DZ - Algeria 5
JM - Giamaica 5
KR - Corea 5
PS - Palestinian Territory 5
AU - Australia 4
BO - Bolivia 4
CI - Costa d'Avorio 4
HN - Honduras 4
JO - Giordania 4
MY - Malesia 4
PA - Panama 4
RO - Romania 4
BB - Barbados 3
CH - Svizzera 3
DO - Repubblica Dominicana 3
KW - Kuwait 3
LV - Lettonia 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
BG - Bulgaria 2
GA - Gabon 2
GE - Georgia 2
GT - Guatemala 2
MM - Myanmar 2
NG - Nigeria 2
NI - Nicaragua 2
QA - Qatar 2
RS - Serbia 2
SN - Senegal 2
SV - El Salvador 2
TH - Thailandia 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BW - Botswana 1
CG - Congo 1
CY - Cipro 1
DK - Danimarca 1
ET - Etiopia 1
GD - Grenada 1
Totale 16.137
Salva come PNG Salva come JPEG
Città #
Dallas 1.235
Singapore 1.056
Hong Kong 992
Shanghai 462
Ashburn 422
Hefei 419
Lawrence 342
Princeton 342
Ho Chi Minh City 271
Beijing 212
São Paulo 195
Moscow 194
New York 149
Hanoi 129
Milan 128
Helsinki 96
Los Angeles 87
Boardman 84
Munich 73
Nuremberg 73
Rio de Janeiro 67
Warsaw 59
Rome 52
Belo Horizonte 40
Dublin 40
Tokyo 38
Cesano Boscone 37
Johannesburg 37
Poplar 35
Santa Clara 35
Montreal 34
Turku 34
Brasília 32
Campinas 32
Denver 32
Chicago 31
Guangzhou 31
London 31
Stockholm 31
Porto Alegre 30
Haiphong 29
Orem 29
Mexico City 26
Biên Hòa 25
Quito 25
Chennai 24
Curitiba 24
Houston 24
The Dalles 24
Phoenix 23
Brooklyn 22
Atlanta 21
Seattle 21
Toronto 21
Da Nang 20
Guarulhos 20
Amsterdam 19
Guayaquil 19
Tashkent 18
Manchester 17
San Francisco 17
Asunción 16
Boston 16
Brescia 16
Columbus 16
Dhaka 16
Goiânia 16
Vienna 16
Washington 16
Osasco 15
Ribeirão Preto 15
Falkenstein 14
Frankfurt am Main 14
Hangzhou 14
Hải Dương 14
Juiz de Fora 14
Tianjin 14
Ankara 13
Aracaju 13
Montes Claros 13
Recife 13
Shenzhen 13
Sorocaba 13
Caxias do Sul 12
Changsha 12
Hortolândia 12
Lappeenranta 12
Maceió 12
Mumbai 12
Romagnano Sesia 12
Bogotá 11
Can Tho 11
Sumaré 11
Thái Bình 11
Thái Nguyên 11
Verona 11
Bắc Giang 10
Casablanca 10
Fortaleza 10
Franca 10
Totale 8.697
Salva come PNG Salva come JPEG
Nome #
Linee guida AIOM per le neoplasie cerebrali. 118
An integrated clinical pathway for pancreatic and periampullary tumor management within the Pancreas Unit network in Lombardy, Italy 114
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma 111
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience 110
Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment - Risk factors analysis 108
A multicenter study of treatment of primary CNS lymphoma 106
A Comprehensive Characterization of Stemness in Cell Lines and Primary Cells of Pancreatic Ductal Adenocarcinoma 101
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial 101
A MULTICENTER TRIAL ASSESSING FEASIBILITY AND EFFICACY OF A COMBINATION OF HIGH-DOSE METHOTREXATE, CYTARABINE AND THIOTEPA IN PATIENTS WITH PRIMARY CNS LYMPHOMA: IMPACT ON OUTCOME OF CYTARABINE DOSE 99
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). 97
A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer 96
Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives 94
EUS-guided GastroEnterostomy for management of malignant Gastric Outlet Obstruction: a prospective cohort study with matched comparison with Enteral Stenting 91
A preoperative score to predict early death after pancreatic cancer resection 88
A four-step method to centralize pancreatic surgery, accounting for volume, performance and access to care 88
Communication, understanding and engagement of patients with pancreatic cancer at time of diagnosis 84
A randomized phase II trial of adjuvant chemotherapy with cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG regimen) or gemcitabine alone after curative resection for pancreatic cancer 84
A multicenter study of the prognosis and treatment of adult brain ependymal tumors 83
Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy 82
Endoscopic ultrasound-guided choledochoduodenostomy versus hepaticogastrostomy combined with gastroenterostomy in malignant double obstruction (CABRIOLET_Pro): A prospective comparative study 81
Diagnostic and therapeutic management of neuroendocrine lung tumors. A clinical study of 44 cases 81
A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile 80
A MULTICENTER RETROSPECTIVE STUDY OF CHEMOTHERAPY IN ADULTS WITH EPENDYMOMA. GICNO (GRUPPO ITALIANO COOPERATIVO NEURO-ONCOLOGIA) 79
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial 78
A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients 78
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients 76
A phase II trial of second-line therapy with trabectedin in metastatic pancreatic adenocarcinoma 75
Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma 74
A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy 73
A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia 73
Quaderni dell’infermiere-Neurologia III edizione 73
Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy 72
A phase II trial of PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced gallbladder, biliary tract, and ampulla of Vater adenocarcinoma, preliminary results 71
ENDOSCOPIC ULTRASOUND-GUIDED HYBRID THERM ABLATION (EUS-HTP) IN PATIENTS (PTS) WITH LOCALLY ADVANCED (LA) PANCREATIC DUCTAL ADENOCARCINOMA (PDAC): A CASE-CONTROL COMPARATIVE SURVIVAL ANALYSIS 71
EUS-guided gallbladder drainage and subsequent peroral endoscopic cholecystolithotomy: A tool to reduce chemotherapy discontinuation in neoplastic patients? 70
Evolving pancreatic cancer treatment: From diagnosis to healthcare management 70
ASO Visual Abstract: The Impact of CT-Assessed Liver Steatosis on Postoperative Complications After Pancreaticoduodenectomy for Cancer 69
3D conformal radiotherapy significantly reduces toxicity of post-prostatectomy adjuvant or salvage irradiation 69
COMMUNI.CARE (COMMUNIcation and Patient Engagement at Diagnosis of PAncreatic CAncer): Study Protocol 68
A RANDOMIZED PHASE II TRIAL OF TWO DIFFERENT FOUR DRUG COMBINATIONS IN ADVANCED PANCREATIC ADENOCARCINOMA: CISPLATIN, CAPECITABINE, GEMCITABINE PLUS EITHER EPIRUBICIN OR DOCETAXEL 68
A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants 66
Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies 65
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial 64
Landscape of Health-Related Quality of Life in Patients with Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review 63
Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial 63
The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma 63
Adjuvant Chemoradiation in Pancreatic Cancer: A Pooled Analysis in Elderly (≥75 years) Patients 63
Postoperative Outcomes and Functional Recovery After Preoperative Combination Chemotherapy for Pancreatic Cancer: A Propensity Score-Matched Study 63
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma 62
Adjuvant chemotherapy in ductal adenocarcinoma of pancreas: a comparison among three regimens 62
ASO Visual Abstract: Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a "Biologic R2 Definition" 61
Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma 60
A retrospective series of upfront therapy in primary brain lymphomas 60
Corneal and Epidermal Nerve Quantification in Chemotherapy Induced Peripheral Neuropathy 60
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 59
The impact of nutritional status on pancreatic cancer therapy 59
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study 59
Prediction of early distant recurrence in upfront resectable pancreatic adenocarcinoma: A multidisciplinary, machine learning-based approach 59
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies 58
Efficacy of endoscopic ultrasound-guided ablation with the hybridtherm probe in locally advanced or borderline resectable pancreatic cancer: A phase ii randomized controlled trial 58
Adjuvant PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) or Gemcitabine Followed by Chemoradiation in Pancreatic Cancer: A Randomized Phase II Trial 58
Isolated lung metastases from pancreatic ductal adenocarcinoma (PDAC): Diagnostic and therapeutic challenges of a different disease 56
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey 56
Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients 56
RNA Extraction from Endoscopic Ultrasound-Acquired Tissue of Pancreatic Cancer Is Feasible and Allows Investigation of Molecular Features 56
Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC). 56
Neoadjuvant chemoradiotherapy in patients with esopageal or esophageal gastric junction cancer 56
A retrospective analysis of postradiation chemotherapy in 133 patients with glioblastoma multiforme 56
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer 55
The Impact of CT-Assessed Liver Steatosis on Postoperative Complications After Pancreaticoduodenectomy for Cancer 55
DIAGNOSTIC DELAY AT DIAGNOSIS AND TIME-TO-TREATMENT INFLUENCE OVERALL SURVIVAL OF PANCREATIC CANCER PATIENTS 55
Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients 55
Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer 54
RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY (CHT) WITH HIGH-DOSE METHOTREXATE (MTX) ALONE OR ASSOCIATED WITH HIGH-DOSE CYTARABINE (ARAC) FOR PATIENTS (PTS) WITH PRIMARY CNS LYMPHOMA (PCNSL): THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG) #20 TRIAL 53
Ibrutinib in Combination with Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Metastatic Pancreatic Adenocarcinoma: Phase 3 RESOLVE Study 53
Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life 52
Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples 52
Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma 52
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer 51
Lessons and open questions in borderline resectable pancreatic cancer 50
Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence 50
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle? 50
Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination 50
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas 49
New era for pancreatic endoscopic ultrasound: From imaging to molecular pathology of pancreatic cancer 49
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients 49
EUS-guided ablation with the HybridTherm Probe as second-line treatment in patients with locally advanced pancreatic ductal adenocarcinoma: A case-control study 48
Solitary clival plasmocytomas: Misleading clinical and radiological features of a rare pathology with a specific biological behaviour. 48
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas 48
Comment on "prognostic Factors of Survival after Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer": What Is Good for the Surgeon Is Just as Good for the Patient? 48
Feasibility of therapeutic endoscopic ultrasound in the bridge-to-surgery scenario: The example of pancreatic adenocarcinoma 47
Randomized phase II trial on primary chemotherapy (CHT) with high-dose methotrexate (MTX) alone or associated with high-dose cytarabine (ARAC) for patients (PTS) with primary CNS lymphoma (PCNSL) 47
Brain metastases (BM) in locally advanced non-small cell lung cancer (LAD-NSCLC) after multimodality treatment (MMT): Risk factors analysis. 47
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 47
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 47
Erratum: Time course of hypothalamic-pituitary deficiency in adults receiving cranial radiotherapy for primary extrasellar brain tumors (Radiotherapy and Oncology 99 (2011) (23-28)) 46
Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets? 46
Comparing 3-, 4- and 6-fields techniques for conformal irradiation of prostate and seminal vesicles using dose-volume histograms 46
Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI survey. 46
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial 45
Totale 6.671
Salva come PNG Salva come JPEG
Categoria #
all - tutte 137.301
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 137.301
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202116 0 0 0 0 0 8 7 1 0 0 0 0
2021/2022329 0 0 0 30 10 2 5 232 18 5 8 19
2022/20231.774 786 437 54 14 13 220 50 92 51 17 23 17
2023/2024871 53 52 88 93 84 132 26 86 23 35 56 143
2024/20255.371 652 118 88 131 165 457 639 455 972 830 399 465
2025/20268.222 1.192 1.392 1.795 2.526 1.246 71 0 0 0 0 0 0
Totale 16.630